1 research outputs found
Novel Medicinal Mushroom Blend as a Promising Supplement in Integrative Oncology: A Multi-Tiered Study using 4T1 Triple-Negative Mouse Breast Cancer Model
Abstract: Although medicinal mushroomextracts have been proposed as promising anti-cancer agents,
their precise impacts on metastatic breast cancer are still to be clarified. For this purpose, the present
study exploited the eect of a novel medicinal mushroom blend, namely Micotherapy U-care, in a 4T1
triple-negative mouse breast cancer model. Mice were orally administered with Micotherapy U-care,
consisting of a mixture of Agaricus blazei, Ophiocordyceps sinensis, Ganoderma lucidum, Grifola frondosa,
and Lentinula edodes. The syngeneic tumor-bearing mice were generated by injecting 4T1 cells in
both supplemented and non-supplemented mice. After sacrifice 35 days later, specific endpoints and
pathological outcomes of the murine pulmonary tissue were evaluated. (i) Histopathological and
ultrastructural analysis and (ii) immunohistochemical assessment of TGF-ß1, IL-6 and NOS2, COX2,
SOD1 as markers of inflammation and oxidative stress were performed. The QoL was comparatively
evaluated. Micotherapy U-care supplementation, starting before 4T1 injection and lasting until the
end of the experiment, dramatically reduced the pulmonary metastases density, also triggering a
decrease of fibrotic response, and reducing IL-6, NOS, and COX2 expression. SOD1 and TGF-ß1
results were also discussed. These findings support the valuable potential of Micotherapy U-care as
adjuvant therapy in the critical management of triple-negative breast cancer